Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, announced the appointment of Lori Kunkel, MD, to its Board of Directors.
April 9, 2024
· 2 min read
